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Abstract
Background: Sustained use of antiretroviral therapy has been consistently shown to be one of the
primary predictors of long-term effectiveness. Switching and discontinuation reflect patient and provider
decisions that may limit future treatment options. In this study, we utilize data reported at semi-annual
study visits from three prospective cohort studies, the AIDS Link to IntraVenous Exposure (ALIVE), the
Women's Interagency HIV Study (WIHS), and the Multicenter AIDS Cohort Study (MACS), to investigate
determinants of HAART modification with a particular focus on reported injection drug use (IDU).
Methods: Longitudinal data collected between 1996 and 2004 contributed from 2,266 participants (37%
with a reported history of IDU) who reported initiating their first HAART regimen during follow-up were
utilized. Separate proportional-hazards models were used to identify factors measured prior to HAART-
initiation associated with the time to first HAART discontinuation and first switch of components of
HAART among continuous HAART users.
Results: The use of PI- vs. NNRTI-based regimens among HAART users with and without any history of
IDU was similar over follow-up. The median time to a first report of discontinuation of HAART was 1.1
years for individuals with a history of IDU but 2.5 years for those without a history of IDU and multivariate
analyses confirmed overall that individuals with a history of IDU were at greater risk for HAART
discontinuation (adj RH = 1.24, 95% CI: 1.03–1.48). However, when restricting to data contributed after
1999, there was no longer any significant increased risk (adj RH = 1.05, 95% CI: 0.81–1.36). After adjusting
for pre-HAART health status and prior ARV exposure, individuals who were ethnic/racial minorities,
reported an annual income < $10,000/year, and were not employed were at significantly greater risk for
HAART discontinuation. The median time to a first change in HAART regimen was approximately 1.5
years after first HAART report and was not elevated among those with a history of IDU (adj RH = 1.09,
95% CI: 0.89–1.34).
Conclusion: Our analyses demonstrate that injection drug use by itself does not appear to be an
independent risk factor for HAART switching or discontinuation in more recent years. However, as
continued HAART use is of paramount importance for long-term control of HIV infection, efforts to
improve maintenance to therapy among disadvantaged and minority populations remain greatly needed.
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Background
Highly active antiretroviral therapy (HAART) has been
unequivocally associated with improved survival among
individuals infected with human immunodeficiency virus
(HIV) and has decreased the incidence of AIDS-associated
opportunistic infections [1,2]. However, as HIV-infected
patients begin to live longer on HAART therapy, issues
regarding viral resistance, short and long-term drug toxic-
ities, and adherence due to complex regimens have
become important concerns [3-5]. These issues, in addi-
tion to the increasing number of treatment options, make
it often necessary to modify therapy in order to achieve
the goals of viral suppression, longer survival, and
improved quality of life [6]. These modifications in treat-
ment, either switching to a new regimen consisting of a
different drug or drugs, downshifting to a non-HAART
treatment regimen, or discontinuation of antiretroviral
use, have uncertain effects on the entire course of disease
and may limit the number of future treatment options [7-
10].
Several previously published studies have characterized
modifications of HAART regimens by determining the
time before HIV patients discontinue or switch to a new
HAART regimen and have investigated correlates of ther-
apy modification or discontinuation [8,10-17]. One fac-
tor that has not been well addressed is whether
individuals with a history of injection drug use (IDU) are
more likely to modify their HAART regimen. Injection
drug use represents a major route of infection in the US
and other parts of the world and presents particular chal-
lenges for HIV treatment, including "the existence of an
array of complicating co-morbid conditions, limited
access to HIV care, inadequate adherence to therapy, med-
ication side effects and toxicities, need for substance abuse
treatment, and the presence of treatment complicating
drug interactions." [18] Previous studies suggest that a his-
tory of injection drug use may be a possible factor in deter-
mining the duration of HAART regimens [11,14]
although few studies of therapy modification have
included substantial numbers of individuals with a his-
tory of injection drug use.
The purpose of this study was to investigate the occurrence
of HAART modifications among individuals enrolled in
the AIDS Link to IntraVenous Experience (ALIVE) study, a
prospective cohort study of individuals with a history of
injection drug use in Baltimore, Maryland [19]. These data
were combined with data from two other US prospective
cohort studies that had a smaller proportion of individu-
als with a history of injection drug use: the Women's Inter-
agency HIV study (WIHS) [20] and the Multicenter AIDS
Cohort Study (MACS) [21]. We compared and contrasted
the frequency of HAART modification among those with
and without a history of IDU across diverse populations,
hypothesizing that participants with a history of IDU
would be more likely to switch or discontinue their initial
HAART regimen. Our approach capitalized on common-
ality of data collection instruments and use of common
variable definitions, selection criteria, and algorithms for
determining HAART regimen changes.
Methods
Study design
The MACS, WIHS, and ALIVE studies are all prospective
studies of HIV infection in the United States. The MACS is
a multicenter study composed of 6,972 men who have sex
with men: 4,954 were recruited in 1984, 668 were
recruited in 1987–1991, and 1350 recruited in 2001–03
in Baltimore, Chicago, Los Angeles, and Pittsburgh. The
WIHS is also a multicenter study, with 2,623 women
recruited in 1994–95 and 1,143 recruited in 2001–02
from New York (2 sites, Bronx and Brooklyn), Chicago,
Los Angeles, San Francisco, and Washington DC. The
ALIVE study, located exclusively in Baltimore, is com-
prised of 3,360 participants with a history of drug injec-
tion, of whom 2,921 were recruited in 1988–89 and 439
were recruited in 1994. All three studies employed similar
follow-up data collection methods in which participants
returned semiannually for a physical examination and an
interview-based questionnaire to obtain information on
demographic and psychosocial factors as well as informa-
tion regarding medical history including antiretroviral
medication use. Participants were asked a series of
detailed questions about each antiretroviral medication
they had taken since their previous visit and whether they
were taking that medication at the time of the study visit.
Photo-medication study aids were used to facilitate the
participants in recalling antiretroviral medication use.
Blood specimens were collected for quantification of
plasma HIV RNA viral load and CD4 cell counts at each
visit using standardized techniques. Additional informa-
tion regarding the study design, population, and demo-
graphics of each study has been reported previously [19-
21].
Definitions of therapy and treatment modification
A participant was considered to be on HAART therapy if
the regimen they reported met one of the following crite-
ria: 1) at least two nucleoside/nucleotide reverse tran-
scriptase inhibitors (NRTIs) with at least one protease
inhibitor (PI) or one non-nucleoside reverse transcriptase
inhibitor (NNRTI), 2) one NRTI and at least one PI and at
least one NNRTI, 3) an abacavir- or tenofovir-containing
regimen with at least 3 NRTIs, 4) a regimen containing
ritonavir and saquinavir and one NRTI, and no NNRTIs.
Combinations of zidovudine and stavudine were not con-
sidered HAART because of their contraindication. This
definition of HAART was in accordance with the guide-
lines for antiretroviral therapy established by the DHHSAIDS Research and Therapy 2007, 4:12 http://www.aidsrestherapy.com/content/4/1/12
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[18]. A participant was considered to be receiving combi-
nation therapy when they reported using two or more
antiretrovirals but their regimen did not meet the above
criteria for HAART. Monotherapy was considered to be the
use of only one antiretroviral of any class.
HAART regimens were grouped into four types depending
upon the class of antiretroviral drugs reported: 1) PI with
no NNRTIs, 2) NNRTI with no PIs, 3) both PI and NNRTI
(dual), or 4) PI and NNRTI sparing (neither a PI nor
NNRTI – i.e. abacavir or tenofovir combinations as
described above). This classification of HAART regimens
was used to evaluate the trends of type of HAART use over
time in the three cohorts.
Modification of HAART regimen was assessed by compar-
ing consecutive semi-annual study visits. Changes from
one visit to the next were classified in three ways [15]: 1)
HAART switching occurred when a regimen was modified
such that at least one drug was different in the regimen but
the participant was still on HAART according to the above
definitions; 2) Downshifting occurred when a participant
who was previously on HAART reported using a less
intense regimen that only met the definitions of either
combo- or monotherapy; 3) Discontinuation  occurred
when a participant stopped using all antiretrovirals com-
pletely. Those HAART users who reported the same regi-
men at consecutive visits were considered stable HAART
users. Participant visits where a combination of drugs
were reported to be used since their last visit that met the
definition of HAART but, at the time of the visit, a regimen
that did not meet our definition of HAART was reported,
were excluded because report of drugs used since the last
visit were not necessarily used concomitantly. Therefore,
this exclusion was implemented to ensure that only par-
ticipants who were unquestionably on HAART regimens
were being evaluated.
Study sample and data analysis
A total of 269 HIV infected participants from ALIVE, 1,301
from WIHS, and 696 from MACS attended a study visit at
least once between April 1, 1996 and April 1, 2004,
reported initiation of HAART while under active follow-
up prior to October 1, 2004 and had pre-HAART CD4+
count data available.
Our analytical methods aimed to accomplish two goals.
First, we assessed longitudinal trends in the use of HAART
by comparing the proportion of HAART use comprised of
each regimen type, as described above. The impact of
cohort (ALIVE, MACS, or WIHS) and injection drug use
history on the prevalence of each of the regimen types (PI
only, NNRTI only, dual PI/NNRTI, and PI/NNRTI spar-
ing) was evaluated using logistic regression models adjust-
ing for calendar year. We adjusted for the correlation
among repeated measurements within a year using gener-
alized estimating equation techniques.
Second, the prevalence of switching, downshifting and
discontinuation over time was examined. To determine
whether history of injection drug use was associated with
HAART modifications, Kaplan-Meier methods and Cox
proportional hazards models [23] were fit to determine
the cumulative incidence and relative hazards of modify-
ing the first HAART regimen. Analyses were conducted
with two different outcomes and risk sets: (1) we used
data from individuals with study visits after HAART initi-
ation to evaluate the time from first reported use of
HAART to the first time of HAART discontinuation or
downshifting, and (2) we used data from individuals
reporting consistent HAART use to evaluate the time from
first reported use of HAART to the first time of switch of
HAART regimen. For each model, the primary exposure
variable of interest was history of injection drug use. Addi-
tional factors included in multivariate models were meas-
ured up to the time of HAART initiation: age at HAART
initiation, race/ethnicity (black, Hispanic, or other), sex,
nadir pre-HAART CD4+ lymphocyte count, peak pre-
HAART HIV viral load, prior AIDS diagnosis, pre-HAART
(baseline) antiretroviral experience, alcohol and tobacco
use, employment, and income. In each of these models,
we adjusted for overall secular trends using calendar time
as a time-varying covariate. However, because the
observed differences in HAART modification patterns
appeared to change over the course of follow-up, we also
report the results of a model limited to data contributed
in 1999 or later (after abacavir had been approved and
began to be reported in the cohorts). This included data
from individuals who initiated HAART in 1999 as well as
from individuals who initiated earlier – the latter contri-
butions are considered left-truncated and contribute to
the analysis using standard staggered (late) entry tech-
niques.
Lastly, we also examined the association of time-varying
report of injection drug use with separate analyses. First,
we included a time-varying indicator of current IDU in the
model that also controlled for history of injection drug
use. Second, we refined the analysis to compare individu-
als reporting current and former injection drug use with
those never reporting a history of injection drug use.
Results
Participant characteristics
Pre-HAART characteristics of the 843 participants with
and 1,423 participants without a history of injection drug
use are presented in Table 1. Of the 269 ALIVE partici-
pants, 100% had a history of injection drug use (by
design), while only 37% (475/1,301) of WIHS partici-
pants and 14% (99/696) of MACS participants had such aAIDS Research and Therapy 2007, 4:12 http://www.aidsrestherapy.com/content/4/1/12
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history. Those without a history of injection drug use had
statistically (p < 0.01) higher nadir CD4+ lymphocyte
count, and were significantly less likely to be Black, non-
Hispanic (and more likely to be White or Hispanic), had
higher education and income, were more likely to be
employed, were less likely to be current smokers or drink-
ers, less likely to have ever been diagnosed with AIDS, and
initiated HAART earlier (pre-1998) than those with a his-
tory of injection drug use.
Patterns and trends of HAART use
The longitudinal trends in the use of HAART by class of
drug are depicted in Figure 1. Both individuals with and
without a history of injection drug use showed a decreas-
ing proportion of PI-based HAART over time, with a small
proportion reporting dual PI/NNRTI and PI/NNRTI spar-
ing regimens. Results from logistic regression analyses did
not show any consistent significant differences between
studies or between individuals with or without injection
drug use. For example, the proportion of participants on
HAART using a PI decreased from 98% in ALIVE, 94% in
MACS, and 93% in WIHS in July 1997 to 51%, 56%, and
56% respectively in January 2004.
Figure 2 displays trends in HAART switching, downshift-
ing and discontinuation between consecutive visits
among those with and without a history of injection drug
use. The proportion of participants on HAART who
reported using the same HAART regimen at their next fol-
low-up visit (stable HAART use) increased considerably
over time in all three studies. Further, the proportion
using the same HAART regimen was higher for those with
no history of injection drug use. For example, the preva-
lence of stable HAART use in those with no history of
injection drug use increased from 55% in 1997 to 70% by
2004. In contrast, the prevalence of stable HAART use in
those with a history of injection drug use started lower,
35%, in 1997 and increased to 65% by 2004. There
appeared to be larger differences between groups prior to
1999. Most modifications to HAART were HAART drug
component switches (20% overall) followed by discon-
tinuation (9% overall) and downshifting to monotherapy
or non-HAART combinations (6% overall). Because of the
relatively small numbers, the discontinuation and down-
shifting outcomes were combined into a single "discon-
tinuation" outcome for subsequent analyses.
Predictors of first HAART modification
For evaluating time to discontinuation, 1,588 individuals
contributed 2,358 person-years with 713 events. The Kap-
lan-Meier estimates of the median time from first HAART
report to first report of discontinuation were notably
shorter for those with (1.1 years) as compared to those
without (2.5 years) a history of injection drug use. Figure
Table 1: Participants' characteristics at first HAART visit
No history of injection drug use History of injection drug use
No. ever reporting HAART 1,423 843
Study (% male):
ALIVE 0 (NA) 269 (72%)
MACS 597 (100%) 99 (100%)
WIHS 826 (0%) 475 (0%)
Race/ethnicity:***
Black, non-hispanic 35% 62%
White, non-hispanic 45% 23%
Hispanic 19% 14%
Median (IQR) nadir CD4 count (cells/mm3)*** 187 (76–315) 152 (64–251)
Median (IQR) peak plasma HIV RNA (cps/ml) 90,606 (25,000–250,000) 84,000 (21,734–269,943)
High school education (vs less)*** 74% 58%
Less than $10,000 legal income*** 39% 72%
Currently employed*** 47% 23%
Current smokers*** 33% 73%
Current drinkers*** 21% 28%
Ever prior AIDS diagnosis*** 34% 45%





PI/No NNRTI 61% 62%
No PI/NNRTI 18% 18%
PI/NNRTI 5% 5%
No PI/No NNRTI 16% 15%
***p < 0.001AIDS Research and Therapy 2007, 4:12 http://www.aidsrestherapy.com/content/4/1/12
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3 displays the cumulative incidence proportion of HAART
discontinuation for the two groups over the entire study
period. These trends were supported by the results of the
Cox regression analysis (Table 2). In univariate analysis,
those with a history of injection drug use had a 78%
higher risk of HAART discontinuation. After adjusting for
pre-HAART health status and other socio-demographic
variables, this elevated risk remained statistically signifi-
cant (adjusted relative hazard (RH) = 1.24, 95% confi-
dence interval (CI): 1.03–1.48). However, when
restricting to data contributed after January 1999 (852
individuals contributing 382 events over 1,396 person-
years), there was no increased risk seen (adj RH = 1.05,
95% CI: 0.81–1.36). Table 2 describes variables that were
significant independent risk factors for discontinuation,
including race/ethnicity, pre-HAART markers (CD4 and
HIV RNA), prior antiretroviral therapy exposure, smok-
ing, low income, and being unemployed.
In separate analyses, we examined the impact of current
and former injection drug use (the latter including those
individuals with a baseline history of injection drug use
but no current active use). The results from these analyses
were similar to those described above: for the entire data-
set, there was an elevated risk of discontinuation among
those reporting current injection drug use (adjusted RH =
1.65, 95% CI: 1.23–2.22) but not former users (adjusted
RH = 1.16, 95% CIL 0.96–1.41) as compared with those
never reporting use. These effects were attenuated when
the data were restricted to 1999 and later (current users
adjusted RH = 1.32, 95% CI: 0.90–1.94; former users
adjusted RH = 1.00, 95% CI: 0.77–1.31).
For evaluating time to HAART regimen switch, 1,211 indi-
viduals contributed 1,931 person-years of continuous
HAART use with 675 switch events. No differences in IDU
Kaplan-Meier estimates of the cumulative incidence propor- tion of individuals with HAART discontinuation Figure 3
Kaplan-Meier estimates of the cumulative incidence propor-
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were apparent in the median time to HAART switch
among consistent HAART users (1.5 years for both). This
was supported by the results of the Cox regression analysis
(Table 2), where both univariate and multivariate analysis
indicated a null association with history of injection drug
use. Time-updated analysis of current injection drug use
showed similar patterns: in comparison to those never
reporting injection drug use, there were no significant
increased risk of HAART switch among current users
(adjusted RH = 1.03, 95% CI: 0.84, 1.28) or former users
(adjusted RH = 1.12, 95% CI: 0.74–1.69).
Discussion
The importance of maintaining patients on consistent,
long-term HAART has been established as an effective
means of suppressing HIV RNA replication and restoring
immune function [1]. The initial HAART regimen is espe-
cially critical in maintaining a positive prognosis by delay-
ing onset of clinical AIDS and allowing for future regimen
options [1,24]. When HIV develops resistance to a drug, it
often develops cross-resistance with several drugs in the
same class, severely limiting future treatment alternatives
[25]. However, despite these concerns, many patients may
need to modify therapy in order to find a regimen that is
more suitable for them, whether to avoid side effects or
increase convenience, or due to virologic failure [12].
Such treatment issues are of particular concern among
HIV-infected injection drug users [26]. Findings from an
earlier study by Chen et al [14] found that a history of
injection drug use was independently associated with the
probability of switching or discontinuing a HAART regi-
men. In this study, we observed that time from HAART
initiation to first regimen modification was significantly
shorter among injection drug users. However, after adjust-
ing for potential confounders and examining data in the
era of more advanced HAART regimens, we observed that
the hazard of HAART modification was attenuated and
not significantly different between those with and without
a history of injection drug use.
These results suggest that other factors may be leading to
the increased risk of HAART modifications in the ALIVE
study and among IDU populations in general. We recog-
nize that a history of IDU in itself may be both con-
founded and a consequence of a variety of factors (e.g.
incarceration, history of physical abuse, etc). Income
level, employment, smoking and alcohol use were shown
to confound the relationship (e.g. the effect of IDU was
attenuated in Model 2 as compared to Model 1) but
adjusting for them did not completely eliminate the asso-
ciation between IDU history and HAART modification.
We did identify several factors that proved to be predictive
Table 2: Relative hazard of HAART discontinuation (including downshifting) and HAART switching among participants initiating 
HAART prior to 10/1/04
HAART Discontinuation HAART Switching
§Model 1: §Model 2: §Model 2 Restricting to data 
contributed after Jan 1999
§Model 1: §Model 2:
Univariate Multivariate Multivariate Univariate Multivariate
History of IDU 1.78 (1.53–2.06) 1.24 (1.03–1.48) 1.05 (0.81–1.36) 0.96 (0.82–1.14) 1.09 (0.89–1.34)
Age at HAART initiation 
(10-year increments)
0.94 (0.85–1.03) 1.03 (0.93–1.15) 0.98 (0.84–1.15) 0.94 (0.84–1.04) 1.02 (0.91–1.14)
Race‡
Black 2.41 (2.02–2.88) 1.84 (1.47–2.29) 1.87 (1.37–2.54) 0.99 (0.84–1.17) 1.19 (0.96–1.48)
Hispanic 2.33 (1.95–2.92) 1.96 (1.50–2.57) 1.74 (1.15–2.65) 1.35 (1.09–1.68) 1.44 (1.10–1.87)
Other 2.86 (1.69–4.85) 2.39 (1.36–4.20) 2.64 (1.12–6.23) 1.18 (0.61–2.30) 1.20 (0.58–2.46)
Male 0.51 (0.43–0.60) 0.85 (0.69–1.05) 1.01 (0.76–1.34) 1.00 (0.86–1.16) 1.17 (0.94–1.45)
Nadir pre-HAART CD4+ 
count
1.23 (1.17–1.30) 1.39 (1.31–1.48) 1.48 (1.36–1.60) 1.18 (1.12–1.24) 1.28 (1.21–1.36)
Peak pre-HAART HIV 
RNA
1.28 (1.16–1.40) 1.34 (1.21–1.48) 1.34 (1.17–1.54) 1.27 (1.15–1.39) 1.32 (1.19–1.47)
Pre-HAART AIDS 
diagnosis
1.26 (1.09–1.47) 0.96 (0.81–1.14) 0.88 (0.70–1.12) 1.17 (0.99–1.36) 1.08 (0.90–1.29)
ART-naïve prior to 
HAART
0.77 (0.64–0.93) 0.85 (0.70–1.05) 0.70 (0.53–0.92) 0.63 (0.51–0.77) 0.66 (0.53–0.83)
Alcohol use** 1.07 (0.90–1.26) 1.07 (0.89–1.28) 1.13 (0.89–1.44) 0.79 (0.66–0.95) 0.81 (0.66–0.99)
Smoking** 1.85 (1.59–2.15) 1.47 (1.20–1.71) 1.39 (1.05–1.84) 0.96 (0.82–1.12) 1.09 (0.91–1.30)
Employed** 0.49 (0.42–0.58) 0.81 (0.67–0.98) 0.84 (0.64–1.09) 0.80 (0.68–0.93) 0.87 (0.72–1.05)
Legal Income <$10,000** 2.33 (2.00–2.72) 1.44 (1.20–1.78) 1.39 (1.05–1.84) 1.21 (1.04–1.41) 1.18 (0.97–1.44)
§ All models adjusted for calendar time
‡ Reference category = White
**Fixed at pre-HAART baselineAIDS Research and Therapy 2007, 4:12 http://www.aidsrestherapy.com/content/4/1/12
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of HAART modification, the strongest and most consist-
ent were measures of HIV disease progression (a higher
pre-HAART peak HIV RNA level, pre-HAART antiretroviral
experience) but also and minority race/ethnicity status.
These findings are consistent with most prior studies that
have investigated HAART regimen modifications
[11,12,16,17], and suggests that these modifications may
occur due to failure of the previous regimen, and may also
be linked to access to care. Previous work by Silverberg et
al [27] working with the US military cohort (which has
racial/ethnic diversity but universal access to health care)
has not demonstrated any differences in HAART effective-
ness by race, thus suggesting that socio-behavioral factors
(e.g. access or quality of care, clinical depression, therapy
adherence) may be more likely determinants of HAART
success. Unfortunately, these were not uniformly meas-
ured in the three cohorts and therefore could not be
assessed as potential confounders in our analyses.
The main limitation of this study is that all data on
antiretroviral use and HAART modification were based on
self-report. Therefore, it is possible that participants may
have misreported or underreported what medications
they were using. However, data on antiretroviral use were
obtained using photo-medication study aids to facilitate
recall of drug usage and both the common and brand
names were used in the interview. Additionally, in an
unpublished analysis performed on a convenience sample
subset of the MACS participants, in which the medical
records were available and abstracted to compare with the
self-reported medication data, it was found that 95% of
the drug records were in concordance with the self-
reported data (L. Jacobson, personal communication).
However, this sub-study was performed only in the MACS
and it is possible that some of the differences seen
between the MACS and ALIVE are due to a higher level of
misreport or lack of recall in the ALIVE study. If true, this
would be an indication of the necessity of increased
patient education among IDUs regarding the medications
they are using with emphasis on the importance of adher-
ence.
The lack of data on viral drug resistance profiles and co-
morbidities among the participants in each cohort is an
additional limitation of this study. Drug resistance and
co-morbidities are an important potential reason for
HAART therapy modification that we were not able to
investigate in this study. A strength of the current study,
however, is its prospective design, allowing for determina-
tion of exposure variables prior to the outcome (e.g.
HAART modifications) using standardized protocols
implemented as part of three long-running interval cohort
studies [28]. Additionally, the common design of all three
parent studies and data collection instruments facilitated
comparisons between the cohorts using compatible cov-
ariates and a common algorithm for the determination of
HAART modifications.
In conclusion, we have demonstrated that in more recent
years there is no impact of reported use of injection drugs
on HAART modification. These data imply efforts to sim-
plify and increase potency of antiretroviral regimens have
been successful at improving HAART maintenance among
a group at high risk for failure. However, the persistent
association of race/ethnicity and low income with HAART
discontinuation provides important direction and moti-
vation for improving methods for HAART utilization
among these high-risk groups.
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